Wire · opportunities
Rasonque's 13.2-month survival result is about to hit hospital formularies
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 August 2026 · Fusion42 review
FDA approved Revolution Medicines' oral drug Rasonque for metastatic pancreatic adenocarcinoma, doubling median survival to 13.2 months, prompting hospitals to integrate it into formularies with new workflow demands on testing, coverage, dispensing, and patient adherence.
This Wire brief sits within Fusion42's coverage of Health, and 46 sources have reported it between 26 Aug 2026 and 30 Aug 2026.
◆ ◆ The Wire takeaway
You face a shift from chemo infusions to tightly integrated oral cancer therapy workflows that demand fast genetic testing and specialty pharmacy coordination to avoid survival losses. Nail your internal pathway definitions and med-to-bed models this week to capture revenue and improve patient outcomes before your peers do.
◆ Coverage
46 sources · first reported 26 Aug 2026 · latest 30 Aug 2026
◆ Topics